Clinical Trials Logo

Filter by:
NCT ID: NCT04149665 Recruiting - Clinical trials for Mechanical Ventilation Complication

Semirecumbent Position by Mechanical Ventilation

Start date: January 11, 2020
Phase:
Study type: Observational [Patient Registry]

It's based in an observational trial in mechanical ventilated patients. The investigators assess the head of bed elevation angle in the routine treatment of the unit. The investigators decide to assess the time the patient has a semirecumbent position >35°.

NCT ID: NCT04148612 Recruiting - Clinical trials for Depressive Disorder, Major

A Study to Evaluate the Benefit of Opti-Me Application to Different Treatments of MDD

Start date: October 6, 2020
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is a debilitating disease characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite. MDD affects one in six adults in their lifetime. To date, decisions regarding specific treatment protocols for MDD are based on clinical experience and risk factors with limited data on outcome prediction. In addition, since it takes 8 weeks to assess if a treatment is successful, the long and often unsuccessful search for an effective antidepressant is accompanied by significant decrease in patients' quality of life, an increased risk of suicidal action, and decreased chance of response and remission with each attempt. This has led to examination of various markers (e.g., neuroimaging, electrophysiological, genetic and behavioral) in an attempt to predict the response to various forms of treatments, including pharmacotherapies and TMS (Transcranial Magnetic Stimulation) for depression. Elminda had developed a novel, non-invasive imaging EEG-based technology, Brain Network Analytics (BNA), for visualization and quantification of specific brain functions. The rationale of the study is to develop a reliable marker for MDD treatment outcome based on the BNA.

NCT ID: NCT04147442 Completed - Hearing Loss Clinical Trials

A Standard Music Program Compared to an Optimized Music Program

Start date: October 9, 2019
Phase: N/A
Study type: Interventional

The trial will test whether a standard music program that is an offset to the general program provides the same benefit as a music program that is individually customized for each test participant. The trial seeks to investigate the benefit received by musicians that regularly play an instrument and belong to an organized music group or orchestra instead of people that listen to music.

NCT ID: NCT04146714 Not yet recruiting - Adolescent Behavior Clinical Trials

Substance Use Screening to Encourage Behavior Change Among Young People in Primary Care

YP-HEALTH
Start date: January 2025
Phase: N/A
Study type: Interventional

This study evaluates whether completing a short screening questionnaire about health behaviours in the waiting room before a primary care consultation decreases excessive substance use in young people aged 14 to 24 years. Young people consulting a primary care physician will randomly receive either a questionnaire about substance use or a questionnaire about physical activity. They will be contacted again 3, 6 and 12 months later and asked to complete a questionnaire about substance use. The proportion of young people with excessive substance use in each group will be compared. The researchers hypothesise that at three months this proportion will be lower in the group of young people having completed the initial questionnaire about substance use when compared to the group having completed the questionnaire about physical activity.

NCT ID: NCT04146389 Terminated - Hyperprolactinemia Clinical Trials

Hyperprolactinemia and Adrenal Steroidogenesis

Prado
Start date: June 24, 2021
Phase:
Study type: Observational

The purpose of this study is to explore the effects of prolactin on adrenal steroid profiles in patients with hyperprolactinemia due to prolactinomas before and after initialisation of treatment.

NCT ID: NCT04146272 Completed - Hearing Loss Clinical Trials

A Comparison of a New Acoustic Feedback Canceller in Hearing Aids With the Current System

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The Purpose of the study is to show that the performance of the new feedback cancellation system is better than the feedback system used in the currently marketed hearing aids. Speech understanding should not be negatively affected by the new system, ad there should be no consequential artifacts or unwanted noises caused by the new system.

NCT ID: NCT04145674 Recruiting - Clinical trials for Restless Legs Syndrome

A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo

Glu-REST
Start date: October 22, 2022
Phase: Phase 2
Study type: Interventional

Proof of concept, double-blind, randomized, placebo-controlled trial with d-methadone proposed for the first time for use in the treatment of patients diagnosed with primary, moderate to very severe Restless Legs Syndrome (RLS). Its glutamatergic mechanism of action might be effective on RLS arousal pattern and sleep disturbance which highly impair the quality of life of RLS's patients. Patients will take the study drug/placebo once a day for 30 consecutive days.

NCT ID: NCT04144998 Completed - Endometriosis Clinical Trials

Central Sensitization and Outcome of Endometriosis Surgery

Start date: October 1, 2019
Phase:
Study type: Observational

This study will evaluate whether the degree of central sensitization as measured by the questionnaire "central sensitization inventory CSI" is related to the outcome of surgical endometriosis treatment

NCT ID: NCT04142437 Recruiting - Clinical trials for Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

ON-TRK
Start date: April 3, 2020
Phase:
Study type: Observational

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.

NCT ID: NCT04141501 Completed - Clinical trials for Alcohol Use Disorder

Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients

Start date: June 8, 2020
Phase: Phase 2
Study type: Interventional

Effects of serotonin 2A/1A receptor stimulation by psilocybin on alcohol addicted patients: a randomized double-blind placebo-controlled study